# US 2024/0316078 A1 · Treatment of Neuropathic Sensitization Disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0316078 A1
- Document ID: US20240316078A1
- Status: Published application
- Kind: A1
- Application number: 18/260,908
- Filed: 2022-01-10
- Published: 2024-09-26
- Earliest claimed: 2021-01-11
- Applicants: IVIEW Therapeutics, Inc.
- Inventors: Edward Tak Wei
- Web page: https://patentgrep.com/patent/US20240316078A1

## CPC

- A61K 31/66: Phosphorus compounds
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 27/02: Ophthalmic agents
- C07F 9/5304: {Acyclic saturated phosphine oxides or thioxides}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

Among others, the present invention provides a method for treating a neuropathic ocular pain disorder in a subject in need thereof, comprising: topically applying a therapeutically effective amount of a 1-di-isopropyl-phosphinoyl-alkane (DIPA) compound onto an ocular surface of the subject for at least one week, wherein the DIPA compound is dissolved in a liquid vehicle which is adapted for focused delivery of the DIPA compound to the ocular surface.

## Claims

### Claim 1

A method for treating a neuropathic ocular pain disorder in a subject in need thereof, comprising topically applying a therapeutically effective amount of a 1-di-isopropyl-phosphinoyl-alkane (DIPA) compound onto an ocular surface of the subject for at least one week, wherein the DIPA compound is dissolved in a liquid vehicle and the liquid vehicle is adapted for focused delivery of the DIPA compound to the ocular surface.

### Claim 2 (depends on 1)

The method of claim 1, wherein the DIPA compound is dissolved in the liquid vehicle at a concentration of 0.5 to 5 mg/ml and the liquid vehicle delivers the DIPA compound to the ocular surface.

### Claim 3 (depends on 1)

The method of claim 1, wherein the liquid vehicle is an aqueous solution.

### Claim 4 (depends on 1)

The method of claim 1, wherein the liquid vehicle is water or isotonic saline.

### Claim 5 (depends on 1)

The method of claim 1, wherein the DIPA compound is dissolved in the liquid vehicle at a concentration of 0.5 to 5 mg/ml.

### Claim 6 (depends on 1)

The method of claim 1, wherein the DIPA compound dissolved in the liquid vehicle is delivered to the ocular surface of the subject with a wipe.

### Claim 7 (depends on 1)

The method of claim 1, wherein the DIPA dissolved in the liquid vehicle is applied 4 times a day to the ocular surface of the subject.

### Claim 8 (depends on 1)

The method of claim 1, wherein the DIPA compound is

### Claim 9 (depends on 1)

The method of claim 1, wherein the DIPA compound is

### Claim 10 (depends on 1)

The method of claim 1, wherein the DIPA compound is

### Claim 11 (depends on 1)

The method of claim 1, wherein the neuropathic ocular pain disorder is caused by dry eye disease or eye surgery.

### Claim 12 (depends on 1)

The method of claim 1, wherein the neuropathic ocular pain disorder is caused by trauma to an eye.

### Claim 13

A topical medication for treating a neuropathic ocular pain disorder in a subject in need, comprising an aqueous solution containing a therapeutically effective amount of a 1-di-isopropyl-phosphinoyl-alkane (DIPA) compound.

### Claim 14 (depends on 13)

The topical medication of claim 13, wherein concentration of the DIPA compound in the aqueous solution is 0.5 to 5 mg/mL.

### Claim 15 (depends on 13)

The topical medication of claim 13, wherein the DIPA compound is

### Claim 16 (depends on 13)

The topical medication of claim 13, wherein the neuropathic ocular pain disorder is caused by dry eye disease.

### Claim 17 (depends on 13)

The topical medication of claim 13, wherein the neuropathic ocular pain disorder is caused by eye surgery.

### Claim 18 (depends on 13)

The topical medication of claim 13, wherein the neuropathic ocular pain disorder is caused by trauma.

### Claim 19

Use of a 1-di-isopropyl-phosphinoyl-alkane (DIPA) compound for manufacturing a medicament for treating a neuropathic ocular pain disorder in a subject in need thereof, wherein the medicament comprises a therapeutically effective amount of the DIPA compound and a liquid vehicle, wherein the liquid vehicle is adapted for focused delivery of the DIPA compound to an ocular surface of the subject.

### Claim 20 (depends on 19)

The use of claim 19, wherein the DIPA compound is
